Terminal complement effectors in atypical hemolytic uremic syndrome: C5a, C5b-9, or a bit of both?

Marina Noris; Giuseppe Remuzzi

doi:10.1016/j.kint.2019.02.038

Related publications

Article2013

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Christophe Legendre, Christoph Licht, Petra Muus, Larry A. Greenbaum, Sunil Babu, Camille L. Bedrosian, Coralie Bingham, D.J. Cohen, Yahsou Delmas, K. Douglas, Frank Eitner, Thorsten Feldkamp, Denis Fouque, Richard R. Furman, Osama Gaber, Maria Herthelius, Maryvonne Hourmant, Diana Karpman, Yvon Lebranchu, Christophe Mariat, Jan Menne, Bruno Moulin, Jens Nürnberger, Masayo Ogawa, Giuseppe Remuzzi, Tristan Richard, Rébecca Sberro‐Soussan, Beth Severino, N. Sheerin, Antonella Trivelli, Lothar Bernd Zimmerhackl, Tim Goodship, Chantal Loirat

Article2012

C5a/C5aR interaction mediates complement activation and thrombosis on endothelial cells in atypical hemolytic uremic syndrome (aHUS)

Sara Gastoldi, Marina Noris, Paolo Macor, Francesco Tedesco, Federica Banterla, Elena Bresin, Roberta Donadelli, Giuseppe Remuzzi, Miriam Galbusera

Article2009

Terminal complement effectors in atypical hemolytic uremic syndrome: C5a, C5b-9, or a bit of both?

Discussion(0)

Related publications

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

C5a/C5aR interaction mediates complement activation and thrombosis on endothelial cells in atypical hemolytic uremic syndrome (aHUS)

Atypical Hemolytic–Uremic Syndrome

Combined Complement Gene Mutations in Atypical Hemolytic Uremic Syndrome Influence Clinical Phenotype

Screening for Complement System Abnormalities in Patients with Atypical Hemolytic Uremic Syndrome